PARP Inhibitors in Epithelial Ovarian Cancers: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Kuo-Hu Chen.

Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. The treatment and prognosis of ovarian cancer depend on the specific tumor histopathologic type. Among all types of ovarian cancers, epithelial ovarian cancers (EOC)s comprise the majority (about 95%); the remainders are malignant germ cell and sex cord-stromal cell tumors. The subtypes of EOCs include high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous ovarian cancers, in which serous cancer is the most common subtype (75%). The majority of patients with advanced-stage ovarian cancers experience relapse and require additional treatment after initial therapy, including an optimal cytoreductive debulking surgery and platinum-based chemotherapy.

  • ovarian cancer
  • PARP inhibitor
  • niraparib

1. Molecular Mechanisms of PARP and PARPi Actions

1.1. The PARP Enzymes

In terms of genetic repair for DNA damages, Poly (ADP-ribose) polymerases (PARP) belong to a family of 17 proteins that play critical roles in different stages of cellular life cycles, including the stress response, chromatin modification, DNA repair, and apoptosis induction (cell death). Among all kinds of PARP, PARP-1 is the most important member due to its role in the DNA repair pathways. Figure 21 shows the structure of PARP-1.
Ijms 23 08125 g002 550
Figure 21. The structure of PARP-1, showing the segments and corresponding functions.
The structure of PARP-1, showing the segments and corresponding functions.
PARP-1 contains three functional domains: a N-terminus DNA-binding domain with zinc finger motifs, a central auto-modification domain that is responsible for releasing the protein from the DNA after catalysis, and a C-terminus catalytic domain (CAT) that houses the protein enzymatic activity and substrate binding sites for nicotinamide-adenine-dinucleotide (NAD+). SSBs often occur after oxidative damages, while DSBs often occur during damages that originate from the injuries of chemical or physical agents. The repair of both SSBs and DSBs is closely related to the PARP actions.

1.2. The Mechanism Underlying Single-Strand Break Repair (SSBR) of DNAs

In the presence of DNA single-strand break (SSB), the DNA-binding domain of PARP binds to the DNA SSB site. Following the activation of NAD+ on the catalytic domain (CAT), PARP initiates the synthesis of polymeric adenosine diphosphate-ribose (Poly (ADP-ribose) or PAR) chain that plays an essential role in recruiting the repairing enzymes for the DNA repair pathway. The targeted enzymes include DNA ligase III, X-ray cross-complementing gene 1 (XRCC1), and DNA polymerase beta (polβ). After repairing SSB, the PAR chains are degraded via Poly (ADP-ribose) glycohydrolase (PARG). Eventually, PARP and repairing complexes dissociate from the DNA for recycling in the future [13,14][1][2]. The base excision repair (BER) pathway of PARP for repairing SBB is illustrated in Figure 32.
Ijms 23 08125 g003 550
Figure 32. The base excision repair (BER) pathway of PARP for repairing SSB.
The base excision repair (BER) pathway of PARP for repairing SSB.

1.3. The Mechanism Underlying Double-Strand Break Repair (DSBR) of DNAs

On the other hand, PARP can also modulate the pathways of DNA double-strand break repair (DSBR) through the recruitment of DSB repair enzymes MRE11 and NBS1, which play key roles in homologous recombination (HR). In addition, PARP also regulates the expression of important HR genes BRCA 1 and RAD51 at a transcription level.
Homologous recombination (HR) and non-homologous end joining (NHEJ) are two main pathways to resolve double-strand breaks (DSBs). HR predominates instead as a mechanism of DNA repair during the S or G2 phase of the cell cycle when a sister chromatid is available to use as a template for in situ repair, in which nucleotide sequences are exchanged between two similar or identical molecules of DNA. It is a high-fidelity, error-free form of DNA repair mechanism and requires functional BRCA proteins for repairing DSBs. In contrast, NHEJ is active throughout all phases of the cell cycle, and it does not require a homologous template that the DNA is simply trimmed and ligated. Given the lack of a contrast template strand, NHEJ is a faster but error-prone mechanism of DNA repair [9,15][3][4]. This error-prone DNA repair often predisposes to genome instability and cell death. Figure 43 shows the repairing process of DSBs via the HR and NHEJ pathways.
Figure 43.
The repairing process of DSBs via the HR and NHEJ pathways.

1.4. BRCA 1 and BRCA 2

BRCA 1 and BRCA 2 are critical proteins involved in the HR of DSBR [16][5].
The MRN complex, composed of MRE11, RAD50, and NBS1, plays an important role in response to DNA damage, while the most well-recognized is as a sensor of DSB to initiate HR. The MRN complex recognizes and binds the DSB to facilitate the recruitment and activation of ATM and ATR kinases that phosphorylate downstream targets, including CHEK2, P53, BRCA1, and H2AX. BRCA 1, assisted by BARD1 and BRIP1, has an active role in signaling DNA damage and in cell-cycle checkpoint regulation that organizes the remaining proteins to the site of repair. The MRN complex then initiates the 5′ to 3′ nucleolytic resection of the DNA to form 3′ overhangs of single-stranded DNA that are bound by RPA. With the assistance of PALB2, BRCA 2 recruits and loads an essential recombination enzyme, RAD51, onto RPA-coated DNA. The RAD51 then invades the homologous DNA strand in a process called strand invasion, allowing the remaining DNA repair to occur with the use of the sister chromatid as the template for error-free repair [9][3].

1.5. PARP Inhibitors: The Mechanisms of Actions

PARP inhibitors compete with NAD+ at the catalytic domain (CAT) of PARP to block PARP catalytic activity and the formation of PAR polymers. These effects compromise the cellular ability to overcome DNA SSB damage (Figure 32). On the other hand, the unrepaired SSBs can be converted to DSBs through the collapse of the replication fork when PARP is inhibited (PARP trapping mechanism). As previously discussed, homologous recombination (HR) is the essential error-free pathway to repair the DNA of DSBs during cell replication, and it requires functional BRCA 1/2 proteins. The process of HR will be blocked in the condition of BRCA 1/2 mutations. The PARP-associated HR pathway can also be partially interrupted by using PARP inhibitors (Figure 43).
The absence of either a functioning base excision repair (BER) pathway or homologous recombination (i.e., HR deficiency or BRCA 1/2 mutations) has no detrimental impact on cell viability, but the deficiency of both together can lead to synthetically lethal death. Untreated cancer cells without BRCA mutation (HR+, BER+), cancer cells without BRCA mutation treated with a PARP inhibitor (HR+, BER−), and untreated BRCA-deficient cancer cells (HR−, BER+) are all viable conditions. However, homologous recombination-deficient (HRD) cancer cells treated with a PARP inhibitor (HR−, BER−) are selectively targeted for synthetically lethal cell death as the DNA repair of both SSBs and DSBs relies above all on NHEJ, the error-prone repair pathway [16][5]. PARP inhibitors have been developed for targeting cancers related to BRCA 1/2 gene mutations.

2. Therapeutic Effects of PARP Inhibitors in Ovarian Cancers: Clinical Trials

2.1. Olaparib

Olaparib is the first PARP inhibitor introduced in clinical practice and has been used for both the maintenance and treatment of ovarian cancers based on a few highly successful clinical trial studies. It was first approved by the FDA in December 2014 as a monotherapy for the treatment of ovarian cancers in germline BRCA-mutated (gBRCAm) patients who have undergone at least three prior lines of chemotherapy, according to the results of a large single-arm, phase II study—Study 42. In this study, an oral dose of olaparib 400 mg BID was given as a monotherapy in 298 patients with gBRCAm ovarian, breast, prostate, and pancreatic cancers who had received at least three prior lines of chemotherapy, of whom 193 patients had recurrent ovarian cancers. In patients with gBRCA1/2m recurrent ovarian cancers, 137/193 had measurable diseases at baseline. Eligible patients were treated continuously until disease progression or other olaparib discontinuation criteria were met. After olaparib treatment, the objective response rate (ORR) was 34% (46/137; 95% confidence interval (CI): 26–42%) and the median duration of response (DOR) was 7.9 months (95% CI: 5.6 months–9.6 months) [17,18][6][7].
In 2017, the olaparib monotherapy was approved by the FDA for maintenance treatment for platinum-sensitive, relapsed ovarian cancers regardless of the presence or absence of BRCA mutations, based on the results of two international, randomized, double-blind, placebo-controlled clinical trials known as Study 19 and SOLO-2, at the dose of 400 mg BID and 300 mg BID, respectively. All patients in both trials had been pre-treated with at least two prior platinum-based chemotherapies. Study 19 was a phase II trial using olaparib as maintenance therapy in relapsed high-grade serous ovarian cancers (HGSOC), fallopian tubes, or primary peritoneal cancers. Notably, the BRCA status (with/without BRAC mutation) was not applied for patient enrollment in this study. A total of 265 patients were randomly assigned to receive either olaparib (n = 136) at a dose of 400 mg BID or placebo (n = 129) after a partial or complete response to their most recent platinum-based chemotherapy. The median progression-free survival (PFS) was significantly longer in the olaparib group than in the placebo group (8.4 months vs. 4.8 months; hazard ratio (HR): 0.35; 95% CI: 0.25–0.49; p < 0.001) [19][8].
SOLO-2 is a phase III trial to evaluate the effect of maintenance treatment with olaparib in BRCA 1/2 mutated patients with platinum-sensitive relapsed ovarian, fallopian tube, and primitive peritoneal cancers. A total of 295 patients were randomized to receive either olaparib (n = 196) at a dose of 300 mg BID or placebo (n = 99) after a partial or complete response to their most recent platinum-chemotherapy. The patients with gBRCAm showed significant improvement in the median PFS when treated with olaparib tablets compared with those treated with the placebo (19.1 months vs. 5.5 months; HR: 0.30; 95% CI: 0.22–0.41, p < 0.0001) [20][9]. In the subsequent report, the median overall survival (OS) was 52 months (95% CI: 41.5 months–59.1 months) in the olaparib group and 39 months (95% CI: 31.4 months–48.6 months) in the placebo group (HR: 0.74, 95% CI: 0.54–1.00) at a median follow-up of 65 months [21][10].
Based on the randomized, double-blind, phase III SOLO-1 trial, the monotherapy of oparalib has furthermore obtained approval to be used for maintenance treatment in patients with newly diagnosed advanced (FIGO stage III–IV), high-grade, BRCA-associated EOCs who have a partial or complete clinical response to first-line platinum-based chemotherapy. In this trial, 391 patients were randomly assigned to either maintenance with olaparib (n = 260) at a dose of 300 mg BID or placebo (n = 131); the patient in both groups had been diagnosed with advanced (FIGO stage III–IV), high-grade, BRCA-associated serous or endometrioid ovarian, fallopian tube or primary peritoneal cancers who had a partial or complete clinical response to platinum-based chemotherapy. A total of 388 patients had a centrally confirmed gBRCAm, and no patients received bevacizumab. After a median follow-up of 41 months, the monotherapy of olaparib resulted in a lower three-year rate of disease progression or death compared with the placebo therapy (60% vs. 27%; HR: 0.30, 95% CI: 0.23–0.41, p < 0.0001), and there was no detriment in health-related quality of life [22][11]. In a post-hoc analysis for the SOLO-1 trial, the median PFS was 56 months (95% CI: 41.9 months not reached) with olaparib versus 14 months with placebo (HR: 0.33; 95% CI: 0.25–0.43) at a median follow-up of five years [23][12]. Based on the objective evidence from SOLO-1, the FDA approved the olaparib monotherapy as the first-line maintenance treatment for patients with platinum-sensitive advanced (FIGO stage III–IV), high-grade, BRCA-associated ovarian cancers in 2018.

2.2. Rucaparib

Rucaparib (CO-338; formerly known as AG-014447 and PF-01367338) is an orally available potent small-molecule PARP inhibitor. It was first approved by the FDA in 2016 and by the EMA in 2018 as a single-agent treatment for patients with advanced ovarian cancers associated with deleterious germline or somatic BRCA mutations who have received two or more chemotherapies. The efficacy of rucaparib as a monotherapy for the treatment of ovarian cancer was initially assessed in two single-arm trials: the phase I–II trial Study 10 and the phase II trial Study 2 (ARIEL 2).
Study 10, published in 2017, was a three-part, open-label, phase I–II study testing the oral single-agent rucaparib: phase I (part 1) was designed to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), and to explore the preliminary efficacy of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors. A total of 56 patients received oral rucaparib (at doses ranging from 40 to 500 mg QD and 240 to 840 mg BID). No MTD was identified using the protocol-specified criteria, and a dose of 600 mg BID was selected as the RP2D based on manageable toxicity and clinical activity. Phase II (part 2A) evaluated the RP2D of oral rucaparib (600 mg BID) in 42 patients with platinum-sensitive, high-grade serous or endometrioid, fallopian tube, or primary peritoneal cancers associated with a germline BRCA1/2 mutation (gBRCAm). The objective response rate (ORR) was 59.5%, with a median duration of response of 7.8 months (95% CI: 5.6 months–10.5 months). In part 2B, rucaparib was tested in patients with relapsed high-grade ovarian cancer (HGOC) with a germline or somatic BRCA1/2 mutation (g/sBRCAm) who had received at least three cycles of prior chemotherapy. Part 3 is ongoing and currently assessing the pharmacokinetics and safety profile of a higher dose of rucaparib in patients with a relapsed solid tumor associated with g/s BRCAm [24][13].
The ARIEL 2 study was a multicenter, two-part, phase II open-label trial investigating the role of rucaparib in recurrent, platinum-sensitive, high-grade ovarian carcinomas after one or more chemotherapy (part 1) and three or four cycles of prior chemotherapy (part 2). The enrollment into ARIEL 2 part 1 is complete, while an extension (part 2) is ongoing. The ARIEL 2 part 1 enrolled 192 patients and classified them into three predefined HRD subgroups: BRCA1/2 mutant (n = 40), BRCA wild-type with loss of heterozygosity (LOH) high (LOH high group, n = 82), and BRCA wild-type and LOH low (LOH low group, n = 70). All patients began to undergo treatment with oral rucaparib at a dose of 600 mg BID for continuous 28-day cycles until disease progression or any other reason for discontinuation. The median PFS after rucaparib treatment was significantly longer in the BRCA-mutated subgroup (12.8 months; HR: 0.27, 95% CI: 0.14–0.44, p < 0.0001), and in the LOH high group (5.7 vs. 5.2 months; HR: 0.62, 95% CI: 0.42–0.90, p = 0.011) compared with the LOH low group [25][14].
Further data to support the usage of rucaparib in multiply relapsed diseases come from a pooled analysis of two phase II studies that were undertaken to characterize the antitumor activity and safety profile of the rucaparib in the eligible patients from Study 10 and ARIEL2 who received a starting dose of oral rucaparib 600 mg BID. The analysis focused on the patients with HGOC and a deleterious germline or somatic BRCA1/2 mutation who received at least two prior chemotherapies: 42 patients were from Study 10 (Part 2A) and 64 from ARIEL 2 (Part 1 and 2). In the efficacy population (n = 106), the overall response rate (ORR) was 53.8% (95% CI: 43.8%–63.5%); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. The median duration of response rate (DOR) was 9.2 months (95% CI: 6.6 months–11.6 months). In addition, 74.5% of the patients exhibited sensitivity to their last platinum-based therapy, 18.8% were platinum-resistant, and 8.4% were platinum-refractory. This integrated safety analysis confirmed the manageable toxicity profile of rucaparib [26][15].
In 2018, the FDA expanded rucaparib indications to the maintenance therapy of recurrent high-grade serous or endometrioid ovarian cancers, fallopian tube cancers, and primary peritoneal cancers, regardless of the presence or absence of BRCA mutations, based on the double-blind, placebo-controlled, phase III ARIEL 3 trial, in which 564 eligible patients had undergone at least two previous platinum-based chemotherapy regimens and achieved complete or partial response to their last platinum-based regimens and were previously PARP-inhibitor-untreated. They were randomly assigned to receive the maintenance therapy with rucaparib (n = 375) at a dose of 600 mg BID or placebo (n = 189) in a 28-day cycle. In contrast to other studies of PARP inhibitors, patients were permitted to be enrolled in this study even if they had residual bulky diseases (≥2 cm). Across all primary analysis groups, rucaparib significantly improved the PFS in patients with platinum-sensitive ovarian cancers who had achieved a response to platinum-based chemotherapy. Rucaparib significantly improved the PFS among those with a known genomic or somatic BRCA mutation (16.6 months vs. 5.4 months; HR: 0.23, 95% CI: 0.16–0.34, p = 0.0001). In patients with a HRD subgroup (236 [63%] vs. 118 [62%]), it was 13.6 months vs. 5.4 months (HR: 0.32, 95% CI: 0.24–0.42; p < 0.0001). In the intention-to-treat (ITT) population, it was 10.8 months vs. 5.4 months (HR: 0.36; 95% CI: 0.30–0.45; p < 0.0001) [27][16].
Rucaparib has shown PFS benefits when combined with chemotherapy in multiple relapsed diseases, as discussed previously in Study 10 and ARIEL. The latest open-label, randomized, controlled, phase 3 study that was published in 2022, ARIEL 4, supports the usage of rucaparib as an alternative treatment option to chemotherapy for patients with relapsed, BRCA1/2 mutated ovarian cancers who have received at least two cycles of previous chemotherapy regimens. The eligible patients were randomly assigned (2:1) to receive oral rucaparib (600 mg BID) or chemotherapy. Patients assigned to the chemotherapy group with platinum-resistant or partially platinum-sensitive disease were given weekly paclitaxel (starting dose 60–80 mg/m2 on days 1, 8, and 15), and those with fully platinum-sensitive disease received platinum-based chemotherapy (single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy). Overall, rucaparib improved the median PFS in comparison to chemotherapy (7.4 vs. 5.7 months, HR: 0.67, 95% CI: 0.52–0.86). Among the patients with platinum-sensitive diseases (progression ≥ 12 months), the PFS was 12.9 months versus 9.6 months for the rucaparib group vs. chemotherapy group (HR: 0.69, 95% CI: 0.37–1.29). Those with partially platinum-sensitive disease (progression during 6–12 months) experienced a PFS of 8.0 months versus 5.5 months (HR: 0.40, 95% CI: 0.24–0.65), respectively. Among those with platinum-resistant disease, the median PFS was 6.4 months versus 5.7 months for rucaparib versus chemotherapy (HR: 0.78, 95% CI: 0.54–1.13) [28][17]. The results of ARIEL 4 revealed the PFS benefit of rucaparib over chemotherapy when used in relapsed ovarian cancers.

2.3. Niraparib

Niraparib (Zejula, TESARO Inc., Waltham, Massachusetts, USA, formerly known as MK-4827) is an orally potent PARP inhibitor and the third FDA-approved PARPi in treating ovarian cancers. In 2017, the FDA approved niraparib for maintenance treatment of all patients with platinum-sensitive, recurrent advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers in complete or partial response to their last platinum-based chemotherapy, irrespective of the BRCA or HRD status based on the randomized, double-blind, phase III NOVA study. A total of 553 eligible patients with recurrent, platinum-sensitive ovarian cancers, fallopian tube cancers, or primary peritoneal cancers with predominantly high-grade serous histologic features were categorized into two independent cohorts on the basis of the presence or absence of a germline BRCA mutation (203 gBRCAm patients and 350 without gBRCAm patients). The patients were randomized to receive niraparib maintenance therapy (300 mg QD) or a placebo after completion of platinum-based chemotherapy until disease progression or unacceptable toxicity. Compared with placebo, niraparib increased the PFS significantly in the experimental niraparib cohorts. Comparing niraparib with placebo, the PFS was 21.0 months vs. 5.5 months in the gBRCAm cohort (HR: 0.27; 95% CI: 0.17–0.41, p < 0.001) and 9.3 months vs. 3.9 months in the overall non-gBRCAm cohort. The PFS of the HRD-positive subgroup in the non-gBRCAm patients was 12.9 months vs. 3.8 months (HR: 0.38; 95% CI: 0.24–0.59, p < 0.001), while the PFS of the HRD-negative and non-gBRCA mutation subgroup was 6.9 vs. 3.8 months (HR: 0.58; 95% CI: 0.36–0.92; p = 0.02) [29][18].
A multicenter, open-label, single-arm, phase II study, QUADRA, evaluated the safety and activity of the niraparib monotherapy. A total of 463 patients with metastatic, relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancers, who had been previously treated with chemotherapy, received oral niraparib 300 mg QD continuously, beginning on day 1 and every cycle (28 days) thereafter until disease progression. In the overall ovarian cancer population, 222 (48%) of 463 patients had HRD-positive tumors (including germlineBRCA-mutated, somatic BRCA-mutated, and non-BRCA-mutated HRD-positive tumors) and 87 (19%) of 463 patients had a germline or somatic BRCA mutation. The median follow-up for overall survival was 12.2 months. In HRD-positive, platinum-sensitive patients who had received ≥3 chemotherapy regimens without prior PARPi therapy, niraparib achieved an ORR of 27.5% (95% CI: 15.9–41.7%), a disease control rate (DCR) of 68.6%, and a DOR of 9.2 months [30][19].
Based on the results, the FDA has approved the usage of niraparib for patients with relapsed, advanced ovarian, fallopian tube, or primary peritoneal cancers treated with three or more prior chemotherapy whose cancers are associated with HRD-positive status in October 2019.
Finally, niraparib has obtained FDA approval as a maintenance therapy in the first-line setting, irrespective of the tumor BRCA status in 2020. Similar to the SOLO-1 results for the olaparib monotherapy, the randomized, double-blind, phase 3 PRIMA trial has demonstrated a remarkable improvement in the PFS with using the niraparib monotherapy as the maintenance treatment of adult patients with primary advanced epithelial ovarian, fallopian tube, or primary peritoneal cancers who are in complete or partial response to first-line platinum-based chemotherapy. Unlike SOLO-1, PRIMA included patients who did not have deleterious mutations in BRCA1/2, and the results showed a significant PFS improvement with the niraparib monotherapy for the overall population, regardless of the presence or absence of HRD [31][20].
A total of 733 patients with newly diagnosed advanced ovarian cancers were randomly assigned in a 2:1 ratio to receive either niraparib or placebo once daily after a response to platinum-based chemotherapy. A statistically significant improvement in the PFS was noted in the patients randomized to niraparib usage compared with placebo usage in the HRD and overall population. In the HRD population, the median PFS was 21.9 months in the patients receiving niraparib and 10.4 months in those receiving placebo (HR: 0.43; 95% CI: 0.31–0.59; p < 0.0001). The median PFS in the overall population was 13.8 months in the patients receiving niraparib and 8.2 months in those receiving placebo (HR: 0.62; 95% CI: 0.50–0.76; p < 0.0001). During the 24-month interim analysis, the rate of overall survival was 84% in the niraparib group and 77% in the placebo group (HR: 0.70; 95% CI: 0.44–1.11) [31][20]. The results of PRIMA revealed the benefit of niraparib usage on the PFS in patients with newly diagnosed advanced ovarian cancers, irrespective of the HRD status.

3. PARP Inhibitors and Antiangiogenic Agents

Angiogenesis is the process of new blood vessel formation that plays an important role in both normal ovarian physiology and ovarian cancer progression [32][21]. Vascular endothelial growth factors (VEGF)s A–D and their receptors (VEGFR)s 1–3 regulate angiogenesis, which is expressed at varying levels on EOC cells. Increased VEGF signaling has been associated with the development of malignant ascites and tumor progression [32,33][21][22]. Antiangiogenic therapies induce a hypoxic cellular state leading to the downregulation of HR repair genes (BRCA1, BRCA2, and RAD51) [34][23]. Angiogenesis inhibitors, such as bevacizumab and cediranib, have demonstrated antitumor activity in ovarian cancers. The monoclonal antibody bevacizumab targets VEGF-A and the small-molecule inhibitor cediranib targets multiple factors, including VEGFRs 1–3 and c-Kit [35][24]. Bevacizumab, in combination with platinum-based chemotherapy, followed by bevacizumab alone as maintenance, has been approved by the FDA for treatment of patients with advanced EOCs after initial surgical intervention, following the results of the GOG-0218 [36][25] and ICON-7 studies [37][26].
The FDA approval for olaparib plus bevacizumab as maintenance therapy for patients with newly diagnosed, advanced, high-grade ovarian cancers who have responded to first-line platinum-based chemotherapy plus bevacizumab is supported by the results of the PAOLA-1 trial [38][27]. In this randomized, double-blind, international phase 3 trial, patients were randomly assigned to two groups of maintenance bevacizumab (15 mg/kg Q21D) with or without olaparib (300 mg BID). The trial reported that in the patients with advanced ovarian cancers who had received first-line standard therapy, including bevacizumab, the addition of maintenance olaparib provided a significant PFS benefit. The benefit was substantial in the patients with HRD-positive tumors, including those without BRCA mutations. After a median follow-up of 22.9 months, a statistically significant improvement was observed in the median PFS for the patients who received olaparib plus bevacizumab versus bevacizumab alone plus placebo (22.1 months vs. 16.6 months; HR: 0.59; 95% CI: 0.49–0.72; p < 0.001). The HRs (Olaparib Group vs. Placebo Group) for disease progression or death were 0.33 (95% CI: 0.25–0.45) in the patients with HRD-positive tumors that had BRCA mutations (the median PFS: 37.2 months vs. 17.7 months), and 0.43 (95% CI: 0.28–0.66) in the patients with HRD-positive tumors that did not have BRCA mutations (the median PFS: 28.1 months vs. 16.6 months), respectively. Among the subgroups with BRCA-positive ovarian cancers, the combination of olaparib plus bevacizumab improved the PFS than bevacizumab alone (37 months vs. 22 months; HR: 0.31, 95% CI: 0.20–0.47) [38][27]. As maintenance therapy, the combination of bevacizumab and olaparib appears beneficial for patients with advanced, high-grade ovarian cancers. However, their synergistic effects remain to be investigated due to the relatively small sample size of the existent studies.

References

  1. Zheng, F.; Zhang, Y.; Chen, S.; Wang, X.; Rao, Y.; Fang, H. Mechanism and Current Progress of Poly ADP-Ribose Polymerase (PARP) Inhibitors in The Treatment of Ovarian Cancer. Biomed. Pharmacother. 2020, 123, 109661.
  2. Loizzi, V.; Del Vecchio, V.; Cicinelli, E.; Cormio, G.; Ranieri, G.; Laforgia, M.; Gadaleta, C.D.; Gargano, G.; Kardhashi, A.; De Liso, M.; et al. PARP Inhibitors and Epithelial Ovarian Cancer: Molecular Mechanisms, Clinical Development and Future Prospective (Review). Oncol. Lett. 2020, 20, 90.
  3. Rose, M.; Burgess, J.T.; O’Byrne, K.; Richard, D.J.; Bolderson, E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front. Cell Dev. Biol. 2020, 8, 564601.
  4. Li, L.Y.; Guan, Y.D.; Chen, X.S.; Yang, J.M.; Cheng, Y. DNA Repair Pathways in Cancer Therapy and Resistance. Front. Pharmacol. 2021, 11, 629266.
  5. Walsh, C.S. Two Decades Beyond BRCA1/2: Homologous Recombination, Hereditary Cancer Risk and A Target for Ovarian Cancer Therapy. Gynecol. Oncol. 2015, 137, 343–350.
  6. Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Mitchell, J.B.G.; Fried, G.; Stemmer, S.M.; Hubert, A.; Rosengarten, O.; et al. Olaparib Monotherapy in Patients with Advanced Cancer and A Germline BRCA1/2 Mutation. J. Clin. Oncol. 2015, 33, 244–250.
  7. Domchek, S.M.; Aghajanian, C.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Balmaña, J.; Mitchell, G.; Fried, G.; Stemmer, S.M.; et al. Efficacy and Safety of Olaparib Monotherapy in Germline BRCA1/2 Mutation Carriers with Advanced Ovarian Cancer and Three or More Lines of Prior Therapy. Gynecol. Oncol. 2016, 140, 199–203.
  8. Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.L.; Meier, W.; Shapira-Frommer, R.; Safra, T.; et al. Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in A Randomised Phase 2 Trial. Lancet Oncol. 2014, 15, 852–861.
  9. Pujade-Lauraine, E.; Ledermann, J.A.; Selle, F.; Gebski, V.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Poveda, A.; Pignata, S.; et al. Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and A BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2017, 18, 1274–1284.
  10. Poveda, A.; Ledermann, J.A.; Selle, F.; Gebski, V.; Floquet, A.; Asher, R.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; et al. Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and A BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2021, 22, 620–631.
  11. Moore, K.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2018, 27, 2495–2505.
  12. Banerjee, S.; Moore, K.N.; Colombo, N.; Scambia, G.; Kim, B.-G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; et al. Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and A BRCA Mutation (SOLO1/GOG 3004): 5-Year Follow-Up of A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2021, 22, 1721–1731.
  13. Kristeleit, R.; Shapiro, G.I.; Burris, H.A.; Oza, A.M.; LoRusso, P.; Patel, M.R.; Domchek, S.M.; Balmaña, J.; Drew, Y.; Chen, L.; et al. A Phase I-II Study of The Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clin. Cancer Res. 2017, 23, 4095–4106.
  14. Swisher, E.M.; Lin, K.K.; Oza, A.M.; Scott, C.L.; Giordano, H.; James, J.; Konecny, G.E.; Coleman, R.L.; Tinker, A.V.; O’Malley, D.M.; et al. Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial. Lancet Oncol. 2017, 18, 75–87.
  15. Oza, A.M.; Tinker, A.V.; Oaknin, A.; Shapira-Frommer, R.; McNeish, I.A.; Swisher, E.M.; Ray-Coquard, I.; Bell-McGuinn, K.; Coleman, R.L.; O’Malley, D.M.; et al. Antitumor Activity and Safety of The PARP Inhibitor Rucaparib in Patients with High-Grade Ovarian Carcinoma and A Germline or Somatic BRCA1 or BRCA2 Mutation: Integrated Analysis of Data from Study 10 and ARIEL2. Gynecol. Oncol. 2017, 147, 267–275.
  16. Coleman, R.L.; Oza, A.M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.I.; Clamp, A.; Scambia, G.; et al. Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma After Response to Platinum Therapy (ARIEL3): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2017, 390, 1949–1961.
  17. Kristeleit, R.; Lisyanskaya, A.; Fedenko, A.; Dvorkin, M.; de Melo, A.C.; Shparyk, Y.; Rakhmatullina, I.; Bondarenko, I.; Colombo, N.; Svintsitskiy, V.; et al. Rucaparib versus Standard-Of-Care Chemotherapy in Patients with Relapsed Ovarian Cancer and A Deleterious BRCA1 or BRCA2 Mutation (ARIEL4): An International, Open-Label, Randomized, Phase 3 Trial. Lancet Oncol. 2022, 23, 465–478.
  18. Mirza, M.R.; Monk, B.J.; Herrstedt, J.; Oza, A.M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J.A.; Lorusso, D.; Vergote, I.; et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl. J. Med. 2016, 375, 2154–2164.
  19. Moore, K.N.; Secord, A.A.; Geller, M.A.; Miller, D.S.; Cloven, N.; Fleming, G.F.; Hendrickson, A.E.W.; Azodi, M.; DiSilvestro, P.; Oza, A.M.; et al. Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial. Lancet Oncol. 2019, 20, 636–648.
  20. González-Martín, A.; Pothuri, B.; Vergote, I.; DePont Christensen, R.; Graybill, W.; Mirza, M.R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2019, 381, 2391–2402.
  21. Monk, B.J.; Minion, L.E.; Coleman, R.L. Anti-Angiogenic Agents in Ovarian Cancer: Past, Present, and Future. Ann. Oncol. 2016, 27 (Suppl. S1), i33–i39.
  22. Sopo, M.; Anttila, M.; Hämäläinen, K.; Kivelä, A.; Ylä-Herttuala, S.; Kosma, V.-M.; Keski-Nisula, L.; Sallinen, H. Expression Profiles of VEGF-A, VEGF-D and VEGFR1 Are Higher in Distant Metastases Than in Matched Primary High Grade Epithelial Ovarian Cancer. BMC Cancer 2019, 19, 584.
  23. Bindra, R.S.; Gibson, S.L.; Meng, A.; Westermark, U. Hypoxia-Induced Down-Regulation of BRCA1 Expression by E2Fs. Cancer Res. 2005, 65, 11597–11604.
  24. Brave, S.R.; Ratcliffe, K.; Wilson, Z.; James, N.H.; Ashton, S.; Wainwright, A.; Kendrew, J.; Dudley, P.; Broadbent, N.; Sproat, G.; et al. Assessing the Activity of Cediranib, A VEGFR-2/3 Tyrosine Kinase Inhibitor, Against VEGFR-1 and Members of The Structurally Related PDGFR Family. Mol. Cancer Ther. 2011, 10, 861–873.
  25. Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; et al. Incorporation of Bevacizumab in The Primary Treatment of Ovarian Cancer. N. Engl. J. Med. 2011, 365, 2473–2483.
  26. Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N. Engl. J. Med. 2011, 365, 2484–2496.
  27. Ray-Coquard, I.; Pautier, P.; Pignata, S.; Pérol, D.; González-Martín, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Mäenpää, J.; et al. Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N. Engl. J. Med. 2019, 381, 2416–2428.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback